March 02, 2024
1 min watch
Save
VIDEO: Ocuphire exec reports successful FDA meeting for oral NPDR treatment
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
ATLANTA — Ocuphire Pharma shared the status of its oral nonproliferative diabetic retinopathy treatment, APX3330, with the optometry community at SECO 2024.
“We had a successful end-of-phase 2 meeting last year with the FDA and we intend to keep the momentum going with a special protocol assessment,” Ocuphire chief business officer, Ronil Patel, MS, said in this Healio video.
APX3330 would offer a noninvasive treatment option for NPDR, according to Patel.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Patel is chief business officer at Ocuphire Pharma.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.